Ferring appoints new Board member
Lausanne, Switzerland – October 2nd, 2002 –
The Board of Directors of Ferring announced this week that Professor Michael Rosenblatt has been appointed to the Group Board.
Prof. Rosenblatt, M. D., has been a member of the Ferring R&D advisory group since 1994. He has broad medical experience and serves on a number of boards in early stage pharmaceutical companies. For ten years he worked for Merck Research Laboratories, where he was Senior Vice President for Research and led multiple R&D programs.
“I’m honored to be asked to join the Board of Directors of a company that has experienced remarkable growth and maturation over the past years. I will bring in a broad experience in drug discovery and a wide network, which can be used to strengthen the Research & Development efforts in the company”, said Prof. Michael Rosenblatt.
Today Prof. Rosenblatt is a renowned professor of Medicine at Harvard Medical School and chief of the Division of Bone and Mineral Research at Beth Israel Deaconess Medical Center. He has been at both institutions since 1992 and has served during that time as President and Harvard Faculty Dean for academic programs at the Medical Center. For the first six years of this period, he was the director of the Harvard-MIT Division of Health Sciences and Technology, a joint venture program directed at training physician-scientists and biomedical engineers. During this time, he was also a professor of Molecular Medicine at Harvard Medical School.
From 1996-1999, Prof. Rosenblatt was the executive director of the Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center.
Frederik Paulsen, Executive Chairman of the Board commented: “We are delighted Prof. Michael Rosenblatt has agreed to further strengthen his relations with Ferring. At Ferring we are committed to providing products that meet genuine patient needs and believe Prof. Rosenblatt’s input will be very valuable in ensuring we continue to rise to that challenge in the years ahead.”
About Ferring Pharmaceuticals
Ferring is a research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, infertility and urology.
In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in over 40 countries.
To learn more about Ferring or our products
please visit us at www.Ferring.com.